Additional Statistical Methodology
Where not available, the HR was estimated using the ratio between probabilities and the 95% CI was estimated using the p-value.

\[ HR_{os} = \frac{\ln(\pi_{experimental})}{\ln(\pi_{control})} \]

Calculating the confidence interval for a ratio (log transformation needed)
For example, in the study reported by Witzens-Harig M, the HR was 0.843, p-value was 0.65, we calculate the CI as follows:
\[ z = -0.862 + \sqrt{0.743 - 2.404 \times \log(0.65)} = 0.472; \]
\[ \text{Est} = \log(0.843) = -0.171; \]
\[ \text{SE} = -0.171/0.472 = -0.362 \text{ but we ignore the minus sign, so SE} = 0.362, \text{ and} \]
\[ 1.96 \times \text{SE} = 0.710; \]
95% CI on log scale = -0.171 - 0.710 to -0.171 + 0.710 = -0.881 to 0.539;
95% CI on natural scale = exp(-0.881) = 0.414 to exp(0.539) = 1.714.
Hence 95% CI of HR is 0.414 to 1.714.

Table S1. Bayesian network meta-analysis of OS.

| Treatment                  | HR (95% CI)                  | HR (95% CI)                  | HR (95% CI)                  | HR (95% CI)                  | HR (95% CI)                  |
|----------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Enzastaurin                | 0.96 (0.34, 2.75)             | 0.9 (0.26, 3.17)              | 1.12 (0.26, 5.03)             | 0.38 (0.02, 7.43)             | 0.72 (0.16, 3.26)             | 1.02 (0.11, 9.62)             |
| Placebo/observation        | 1.04 (0.36, 2.97)             | 0.94 (0.49, 1.84)             | 1.17 (0.42, 3.36)             | 0.39 (0.02, 6.48)             | 0.75 (0.25, 2.19)             | 1.05 (0.14, 7.86)             |
| Rituximab                  | 1.11 (0.32, 3.79)             | 1.07 (0.54, 2.04)             | 1.26 (0.36, 4.28)             | 0.42 (0.02, 7.39)             | 0.8 (0.22, 2.78)              | 1.13 (0.14, 9.13)             |
| Lenalidomide               | 0.89 (0.2, 3.88)              | 0.85 (0.3, 2.4)               | 0.8 (0.23, 2.78)              | 0.34 (0.02, 4.65)             | 0.64 (0.14, 2.88)             | 0.9 (0.1, 8.32)               |
| Lenalidomide & rituximab   | 2.65 (0.13, 50.58)            | 2.56 (0.15, 41.17)            | 2.4 (0.14, 41.78)             | 2.97 (0.21, 41.58)            | Lenalidomide & rituximab      | 1.93 (0.1, 36.66)             | 2.69 (0.09, 82.32)            |
| Thalidomide                | 1.39 (0.31, 6.22)             | 1.34 (0.46, 3.92)             | 1.25 (0.36, 4.45)             | 1.56 (0.35, 6.97)             | 0.52 (0.03, 10.51)            | 0.71 (0.13, 7.85)             |
| Everolimus                 | 0.98 (0.1, 9.17)              | 0.95 (0.13, 7.01)             | 0.89 (0.11, 7.36)             | 1.11 (0.12, 10.47)            | 0.37 (0.01, 11.49)            | 0.71 (0.13, 3.92)             |
Figure S1. Surface under the cumulative ranking (SUCRA) of the treatments.